These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 37004047)

  • 1. CAR T-Cell therapy for the management of mantle cell lymphoma.
    Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
    Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM
    J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
    Anderson MK; Torosyan A; Halford Z
    Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
    J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase¬†Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
    Tbakhi B; Reagan PM
    Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
    Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
    Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
    Mian A; Hill BT
    Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715
    [No Abstract]   [Full Text] [Related]  

  • 15. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
    Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jimenez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Nunes A; Reitan J; Wade SW; Salles G
    Leuk Lymphoma; 2024 Jan; 65(1):14-25. PubMed ID: 37840282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
    Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
    J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Dong J; Adhikary S; Zhou L; Schuberth PC; Faghmous I; Masouleh BK; Houot R
    J Hematol Oncol; 2022 Dec; 15(1):170. PubMed ID: 36494725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
    Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
    [No Abstract]   [Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
    Marchetti M; Visco C
    Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.